A 144-week real-world outcomes of upadacitinib 30 mg for atopic dermatitis in poor responders to 15 mg

Supplementary Figure 1. Individual patient transitions of serum immunoglobulin E (IgE) and thymus and activation-regulated chemokine (TARC) at weeks 0, 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, and 144 after dose increase of upadacitinib to 30 mg in patients with atopic dermatitis with insufficient response to 15 mg (n = 28). Each line represents one patient with available data (observed cases). Missing data were not imputed.

Supplementary Table 1. Baseline demographic and disease characteristics of patients with atopic dermatitis switched to upadacitinib 30 mg treatment from upadacitinib 15 mg (n = 28)

Supplementary Table 2. Treatment-emergent adverse events (TEAEs) during 144-week treatment of upadacitinib 30 mg in patients with atopic dermatitis switched from upadacitinib 15 mg (n = 28)

补充图1. 针对15mg乌帕替尼（upadacitinib）应答不足的特应性皮炎患者，将乌帕替尼剂量上调至30mg后，于给药后第0、4、12、24、36、48、60、72、84、96、108、120、132、144周的血清免疫球蛋白E（immunoglobulin E, IgE）与胸腺与活化调节趋化因子（thymus and activation-regulated chemokine, TARC）的个体患者时序变化（n=28）。每条线条代表1例存在有效观测数据的患者，未对缺失数据进行插补。

补充表1. 从15mg乌帕替尼换用30mg乌帕替尼治疗的特应性皮炎患者的基线人口学特征与疾病特征（n=28）

补充表2. 针对从15mg乌帕替尼换用30mg乌帕替尼的特应性皮炎患者，在144周治疗期间出现的治疗期不良事件（treatment-emergent adverse events, TEAEs）情况（n=28）